Thus, therapeutically increasing insulin doses may result in increased peripheral hyperinsulinemia in patients with DM-NAFLD, further increasing the risk of hypoglycemia. The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.